Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Advertisement

Breast malignant, males, children

Breast cancer

Sentinel lymph nodes


Reviewer: Monika Roychowdhury, M.D. (see Reviewers page)
Revised: 19 December 2012, last major update February 2012
Copyright: (c) 2001-2012, PathologyOutlines.com, Inc.

General
=========================================================================

● Sentinel node is first node to which lymphatic drainage and metastasis from breast cancer occurs
● Usually an axillary node in central group of level I, but may be at level II (behind the pectoralis minor muscle), level III (infraclavicular) or be intramammary, interpectoral (Rotter's) or internal mammary node (Eur J Surg Oncol 2009;35:252)
● Tumor is more likely at inflow junction of afferent lymphatic vessel (Am J Surg Pathol 2003;27:385)

Clinical
=========================================================================

● Sentinel node may have characteristics that prevent further tumor spread up the lymphatic chain (Int Semin Surg Oncol 2006;3:39)
Procedure: surgeon injects blue dye or radioactive colloid around tumor, which travels to and identifies the first draining sentinel lymph node; extensive pathologic examination is performed of sentinel node (see below) to look for micrometastases
● If sentinel node(s) is negative, other nodes are negative in >95% of cases; axillary recurrence rate is only 0.3% at median 34 months (Eur J Surg Oncol 2008;34:1277)
● Considered a suitable replacement for axillary dissection for staging/diagnosis in T1 and T2 tumors, with reduced patient morbidity because fewer lymph nodes are removed (Ann Surg OncolM 2008;15:1996); may have a role in microinvasive disease (Breast J 2008;14:335)
● Intraoperative frozen section (World J Surg Oncol 2008;6:69), intraoperative imprint cytology (Eur J Surg Oncol 2009;35:16) or molecular assays may be useful (J Clin Oncol 2008;26:3338)
● Frozen section had 60% sensitivity and 100% specificity in one study, with “atypical” cases usually negative on permanent sections (Mod Pathol 2005;18:58); concentrated smear technique is more sensitive than direct smears (Am J Clin Pathol 2004;122:944)
● High risk (60%) of tumor in nonsentinel nodes if sentinel node has macroscopic tumor (2 mm or more) versus low risk (3%) if microscopic tumor (0.2 to 2 mm, Mod Pathol 2005;18:762)
● Micrometastases may not affect survival (Ann Oncol 2009;20:41, J Clin Oncol 2009;27:4679) but see J Am Coll Surg. 2009;208:333
● In addition, cohesive cluster of malignant cells, 0.2 mm to 2.0 mm, may indicate significant axillary disease; smaller clusters are highly unlikely to be associated with significant residual metastasis or poor prognosis
● May be useful even after neoadjuvant [preoperative] chemotherapy (Acad Radiol 2009;16:551)
● In transit metastasis - metastases in lymph nodes other than sentinel node, that are associated with afferent lymph vessels to the sentinel node but not are typically removed during sentinel node procedure (J Clin Pathol 2008;61:1314)
● Memorial Sloan-Kettering Cancer Center nomogram is useful to surgeons to predict likelihood of non-sentinel lymph node axillary metastases (Ann Surg Oncol 2003;10:1140, J Am Coll Surg 2009;208:229)
● Recommendations for handling radioactive specimens at: Am J Surg Pathol 2000;24:1549
● Pre-operative axillary ultrasound and fine needle aspirate cytology (FNAC) are routine at many breast units, with a sensitivity of 56% (confidence interval: 47-64%) and specificity of 90% (84-93%) for ultrasound alone, and 76% (61-87%) and 100% (65-100%) combined with FNAC (Breast. 2011 Oct 5. [Epub ahead of print]); its use before sentinel lymph node biopsy significantly increases the identification rate and decreases the false negative rate (J BUON 2011;16:454)

Isolated tumor cells
=========================================================================

● Single cells in lymph nodes interpreted as malignant; clinical significance has not yet been demonstrated
● Primary tumors associated with sentinel nodes with isolated tumor cells have more lymphovascular invasion and higher proliferative rate than primaries without nodal involvement, but less lymphovascular invasion, lower proliferative rate and smaller tumor size than primary tumors with micro- or macrometastases (Surgery 2008;144:518)
● May represent benign epithelium or degenerated malignant cells (Am J Surg Pathol 2009;33:106, Hum Pathol 2009;40:778)

Consensus recommendations
=========================================================================

References: Hum Pathol 2002;33:579
● Submit entire node unless gross tumor
● Slice large nodes into 3-4 mm thick sections and submit all

● Other possible protocols if examination of initial H & E stained section does not reveal metastases:
(1) Obtain 2 additional hematoxylin and eosin-stained sections and one pancytokeratin (AE1-AE3) stained section (Am J Surg Pathol 2002;26:377)
(2) Obtain 3 additional H & E stained sections (no immunohistochemistry since occult metastases have minimal predictive value, Mod Pathol 2002;15:641), or:
(3) Cut into 2 mm slices, obtain 5 levels for each slice - 2 H&E, 3 AE1-AE3 (Arch Pathol Lab Med 2003;127:701, Arch Pathol Lab Med 2009;133:1437)
(4) Complete sectioning through block detects additional micrometastases, but raises cost effectiveness concerns (Am J Surg Pathol 2009;33:1583)

Note: AE1-AE3 is better than CAM 5.2 since less staining of reticulum cells (Arch Pathol Lab Med 2000;124:1310)

False positives with cytokeratin
=========================================================================

● Benign epithelial cells are associated with pre-sentinel biopsy breast massage (Am J Surg Pathol 2004;28:1641)
● Benign glandular inclusions (Am J Clin Pathol 2008;130:21)
● Ectopic breast tissue (Am J Surg Pathol 2003;27:513)
● Megakaryocytes (Arch Pathol Lab Med 2002;126:618, image)
● Mesothelial cell inclusions
● Nevus cells (Eur J Dermatol 2008;18:586)
● Reticulum cells may be AE3+ (Arch Pathol Lab Med 2002;126:248, image), less of a problem with AE1-AE3)
● Sclerosing adenosis (Arch Pathol Lab Med 2008;132:1439)
● Wrong antibody (Arch Pathol Lab Med 2001;125:1497)

Case reports
=========================================================================

● 45 year old woman with distinct populations of infiltrating ductal carcinoma and lobular carcinoma in both breast and sentinel lymph node (Arch Pathol Lab Med 2004;128:365)
● Level III sentinel node (World J Surg Oncol 2006;4:31)

Clinical images
=========================================================================



Blue stained axillary node

Micro images
=========================================================================



Fig 1: micrometastases-H&E
Fig 2: micrometastasis-AE1/AE3+



Isolated tumor cells are AE1/AE3+


Fig 1: negative H&E
Fig 2: AE1/AE3 demonstrates micrometastasis



Isolated tumor cells and micrometastasis


False positive cases


Erroneous use of lamda light chain, which
stains plasma cells, instead of AE1/AE3



Sclerosing adenosis, not tumor


Micrometastases: H&E and keratin


Clusters and single cells highlighted with pan-keratin antibody

Additional references
=========================================================================

Am J Surg Pathol 2002;26:383 (other recommendations), Am J Surg Pathol 2003;27:842 (which micrometastases are significant), Wikipedia, eMedicineHealth

End of Breast malignant, males, children > Breast cancer > Sentinel lymph nodes


This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).